Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + ATRA + ATO in Newly Diagnosed APL with Hyperleukocytosis
NCT07187505Active, not recruiting
- Sponsor
- Anhui Medical University
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of venetoclax in acute promyelocytic leukemia (APL), sponsored by Anhui Medical University. Primary endpoints: Early Mortality (Day 0-30) at 30 days, Complete Remission at Day 28 and 2 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT07187505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187505.